After-Hours Stock Movers 02/24: (MRNA) (MMSI) (NLS) Higher; (PANW) (EVER) (SHAK) Lower (more...)

Go back to After-Hours Stock Movers 02/24: (MRNA) (MMSI) (NLS) Higher; (PANW) (EVER) (SHAK) Lower (more...)

Kratos Defense (KTOS) Secures Contract from Northrop Grumman (NOC) to Support U.S. Air Force Ground Based Strategic Deterrent Program

February 26, 2020 8:14 AM EST

Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leading National Security Solutions provider, announced today that its Command, Control, Communications, Computing, Combat & Intelligence, Surveillance and Reconnaissance (C5ISR) Division has been... More

Moderna (MRNA) Tops Q4 EPS by 5c

February 26, 2020 7:16 AM EST

Moderna (NASDAQ: MRNA) reported Q4 EPS of ($0.37), $0.05 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $14.06 million versus the consensus estimate of $17.37 million.

The Moderna team continues to execute our strategy, including our CMV Phase 2 study enrolling ahead of plan,... More

Loop Capital Upgrades HP, Inc. (HPQ) to Buy

February 25, 2020 6:39 AM EST

Loop Capital analyst Ananda Baruah upgraded HP, Inc. (NYSE: HPQ) from Hold to Buy with a price target of $28.00 (from $19.00).

For an analyst ratings summary and ratings history on HP, Inc. click here. For more ratings news on HP, Inc. click here.

Shares of HP, Inc. closed at $22.70 yesterday.

... More

RBC Capital Downgrades Palo Alto Networks (PANW) to Sector Perform

February 25, 2020 6:08 AM EST

RBC Capital analyst Matthew Hedberg downgraded Palo Alto Networks (NYSE: PANW) from Outperform to Sector Perform with a price target of $235.00 (from $280.00).

The analyst comments "Following another mixed quarter/outlook, we are reducing our rating to SP and our target to $235. Changes... More

Moderna (MRNA) Reports First Shipment of mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

February 25, 2020 5:51 AM EST

Moderna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients today announced that it has released the first batch of mRNA-1273, the Companys vaccine against the novel coronavirus, for human use. Vials of mRNA-1273 have been shipped to the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) to be used in the planned Phase 1 study in the U.S.

mRNA-1273 is an mRNA vaccine against the novel... More